Back to Search
Start Over
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual
- Source :
- Annals of the rheumatic diseases. 78(12)
- Publication Year :
- 2019
-
Abstract
- BackgroundThe European Scleroderma Trials and Research Group (EUSTAR) recently developed a preliminarily revised activity index (AI) that performed better than the European Scleroderma Study Group Activity Index (EScSG-AI) in systemic sclerosis (SSc).ObjectiveTo assess the predictive value for short-term disease severity accrual of the EUSTAR-AI, as compared with those of the EScSG-AI and of known adverse prognostic factors.MethodsPatients with SSc from the EUSTAR database with a disease duration from the onset of the first non-Raynaud sign/symptom ≤5 years and a baseline visit between 2003 and 2014 were first extracted. To capture the disease activity variations over time, EUSTAR-AI and EScSG-AI adjusted means were calculated. The primary outcome was disease progression defined as a Δ≥1 in the Medsger’s severity score and in distinct items at the 2-year follow-up visit. Logistic regression analysis was carried out to identify predictive factors.Results549 patients were enrolled. At multivariate analysis, the EUSTAR-AI adjusted mean was the only predictor of any severity accrual and of that of lung and heart, skin and peripheral vascular disease over 2 years.ConclusionThe adjusted mean EUSTAR-AI has the best predictive value for disease progression and development of severe organ involvement over time in SSc.
- Subjects :
- Male
medicine.medical_specialty
Index (economics)
Multivariate analysis
Time Factors
Accrual
systemic sclerosis
2745 Rheumatology
Immunology
610 Medicine & health
autoimmune disease
Logistic regression
Severity of Illness Index
General Biochemistry, Genetics and Molecular Biology
Scleroderma
outcomes research
Rheumatology
1300 General Biochemistry, Genetics and Molecular Biology
Predictive Value of Tests
Internal medicine
Immunology and Allergy
Medicine
Humans
autoimmune diseases
Prospective Studies
2403 Immunology
Clinical Trials as Topic
Scleroderma, Systemic
business.industry
Vascular disease
10051 Rheumatology Clinic and Institute of Physical Medicine
Middle Aged
medicine.disease
Prognosis
Europe
2723 Immunology and Allergy
Disease Progression
Female
Outcomes research
Group activity
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 14682060
- Volume :
- 78
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- Annals of the rheumatic diseases
- Accession number :
- edsair.doi.dedup.....2eee8e12cfab2ceed12ccec24ea3879c